

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Antonio Marchetti et al.

Application No.: To be assigned

Filed: Herewith

Confirmation No.: To be assigned

For: NUCLEOTIDE AND DEDUCED AMINO
ACID SEQUENCES OF TUMOR GENE
INT6

Examiner: To be assigned

Art Unit: To be assigned


Attorney Reference No.: 4239-67782

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV331581431US in an envelope addressed to: MAIL STOP PATENT APPLICATION COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed February 19, 2004



MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/858,152, which was filed May 14, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67782
		Application Number	To be assigned
		Filing Date	Herewith
		First Named Inventor	Antonio Marchetti
		Art Unit	To be assigned
		Examiner Name	To be assigned
U.S. PATENT DOCUMENTS			
Examiner's Initials*	Cite No. (optional)	Number	Date
FOREIGN PATENT DOCUMENTS			
Examiner's Initials*	Cite No. (optional)	Number	Date
OTHER DOCUMENTS			
		Dickson et al., <i>Cell</i> 37:529-536, 1984	
		Diella et al., <u>10th Annual Meeting on Oncogenes</u> , Frederick, MD, 1994	
		Diella et al., <i>DNA and Cell Bio.</i> 16:839-847, 1997	
		Gallahan et al., <i>J. Virol.</i> 61(1):66-74, 1987	
		Jhappen et al., <i>Genes & Develop.</i> , 6:345-355, 1992	
		Marchetti et al., <u>7th Annual Meeting on Oncogenes</u> , Frederick, MD, 1991	
		Marchetti et al., <i>J. Virol.</i> 69(3):1932-1938, 1995	
		Miyazaki et al., <u>9th Annual Meeting on Oncogenes</u> , Frederick, MD, 1993	
		Miyazaki et al., <i>Genomics</i> 27:420-424, 1995	
		Muller et al., <i>Embo. J.</i> 9:907-913, 1990	
	,	Nucleic Acid Sequence having GenBank Accession No. D11956	
		Nucleic Acid Sequence having GenBank Accession No. Z25267	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67782
Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Antonio Marchetti
Art Unit	To be assigned
Examiner Name	To be assigned

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.